



BioLineRx to Present at the LD Micro Main Event

November 24, 2015

TEL AVIV, Israel--(BUSINESS WIRE)--Nov. 24, 2015-- BioLineRx Ltd. (NASDAQ, TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer, Kinneret Savitsky, Ph.D., and its Chief Financial and Operating Officer, Philip Serlin, will be presenting at the [LD Micro Main Event](#) on December 2, 2015. The presentation will take place at 10:00 a.m. PST at the Luxe Sunset Boulevard Hotel in Los Angeles, CA.

About BioLineRx

BioLineRx is a publicly-traded, clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates. The Company in-licenses novel compounds primarily from academic institutions and biotech companies based in Israel, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization.

BioLineRx's current portfolio consists of a variety of clinical and pre-clinical projects, including: BL-8040, a cancer therapy platform, which is in the midst of a Phase 2 study for relapsed/refractory AML, has recently initiated a Phase 2b study as an AML consolidation treatment, has recently initiated a Phase 1/2 study in hMDS and AA, and has successfully completed a Phase 1 study in stem cell mobilization; and BL-7010 for celiac disease, which has successfully completed a Phase 1/2 study.

In December 2014, BioLineRx entered into a strategic collaboration with Novartis for the co-development of selected Israeli-sourced novel drug candidates. The companies intend to co-develop a number of pre-clinical and early clinical therapeutic projects through clinical proof-of-concept for potential future licensing by Novartis.

For more information on BioLineRx, please visit www.bioplinrx.com or download the investor relations mobile device app, which allows users access to the Company's SEC documents, press releases, and events. BioLineRx's IR app is available on the iTunes App Store as well as the Google Play Store.

View source version on businesswire.com: <http://www.businesswire.com/news/home/20151124005375/en/>

Source: BioLineRx Ltd.

PCG Advisory

Vivian Cervantes, 212-554-5482

Investor Relations

vivian@pcgadvisory.com

or

for BioLineRx Ltd.

Tsipi Haitovsky, +972-3-624-0871

Public Relations

tsipihai5@gmail.com